<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808429</url>
  </required_header>
  <id_info>
    <org_study_id>MS700461-0035</org_study_id>
    <secondary_id>2016-002262-31</secondary_id>
    <nct_id>NCT02808429</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Atacicept in IgA Nephropathy</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This main purpose of this study was to evaluate the safety, tolerability, dose response and
      efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The
      study hypothesis was that treatment with Atacicept would reduce proteinuria compared to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Actual">February 7, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Proportion of subjects with Adverse events (AE), AEs of special interest (AESIs), serious AEs, AEs leading to discontinuation, and AEs leading to death</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Percent change from baseline in proteinuria at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Serum atacicept concentrations</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline levels in serum immunoglobulin (Ig) classes (IgG, IgA, and IgM)</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in serum Galactose Deficient-IgA1 (Gd-IgA1) levels</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in serum complement C3 and C4 levels</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in immune cell subsets by flow cytometry analysis</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change in urine immuno-electrophoresis pattern</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of subjects positive for Anti-drug antibody assessment</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of subjects with Clinical significant abnormalities in laboratory assessments, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects achieving reduction in proteinuria from Baseline and with stable renal function</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from Baseline in Renal Function</measure>
    <time_frame>Baseline, Week 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Serum atacicept concentrations</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline levels in serum immunoglobulin (Ig) classes (IgG, IgA, and IgM)</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in serum Galactose Deficient-IgA1 (Gd-IgA1) levels</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in serum complement C3 and C4 levels</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in immune cell subsets by flow cytometry analysis</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in urine immuno-electrophoresis pattern</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects positive for Anti-drug antibody assessment</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with AEs, AESIs, AEs leading to discontinuation, SAEs, AEs leading to death</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with Clinical significant Abnormalities in laboratory assessments, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacicept 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacicept 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection for 72 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 25 mg</intervention_name>
    <description>Partcipants received 25 milligrams (mg) of Atacicept once weekly as SC injection for 72 weeks.</description>
    <arm_group_label>Atacicept 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 75 mg</intervention_name>
    <description>Partcipants received 75 mg of Atacicept once weekly as SC injection for 72 weeks.</description>
    <arm_group_label>Atacicept 75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to (&gt;=)18 years of age

          -  Biopsy-proven Immunoglobulin (IgA) nephropathy

          -  Urine Protein to Creatinine Ratio (UPCR) &gt;= 0.75 and &lt;= 6 milligram per milligram
             (mg/mg) during screening

          -  Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or
             angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening

        Exclusion Criteria:

          -  Concomitant significant renal disease other than IgA nephropathy

          -  IgA nephropathy with significant glomerulosclerosis or cortical scarring

          -  Diagnosis of Henoch-Schonlein purpura

          -  Failure to meet estimated glomerular filtration rate (eGFR) and biopsy requirement
             criteria

          -  Serum IgG below 6 grams per liter (g/L)

          -  Use of cyclophosphamide ever or use of other immunosuppressants or systemic
             corticosteroids within 4 months

          -  Active infection requiring hospitalization or treatment with parenteral
             anti-infectives within 4 weeks

          -  History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB
             infection

          -  History of or positive HIV and/or positive for hepatitis B or Hepatitis C at screening

          -  History of malignancy

          -  Nursing or pregnancy

          -  Any condition, including any uncontrolled disease state other than IgA nephropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKDHC Medical Research Services, LLC.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research - Chula Vista Location</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Kidney Care PC - Dr. Marder</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Clinical Research Institute, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GA Nephrology Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrotex Research Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center &amp; Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital - Dept of Nephrology/Hypertension</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust - ULTIMATE PARENT</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700461-0035</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atacicept</keyword>
  <keyword>IgA Nephropathy</keyword>
  <keyword>BergerÂ´s disease</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website.</ipd_description>
    <ipd_url>https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

